The SURMOUNT-5 trial (published in NEJM, 2025) demonstrated mean weight loss of 20.2% with tirzepatide versus 13.7% with semaglutide over 72 weeks in adults with obesity but without diabetes [10]
While previous studies have compared GLP-1R/GCGR and GLP-1R agonists, the current study appears to be the first to directly compare a GLP-1R/GCGR and a PPAR-/ agonist, demonstrating statistically improved activity of ALT-801 over elafibranor in most NASH measures
The FDA has determined that product use is not likely to cause adverse health consequences
Another disadvantage may be related to the flavor or texture of the lozenge.[] Oral suspensions and solutions have not yet gained popularity due to their sulfurous taste
In trials, the drug caused thyroid C-cell tumors in rodents, although it is unknown whether Zepbound can result in the same cancer in humans
Our Chicago location makes it easy to get expert care and start your Wegovy weight loss journey today
